US equity markets are entering an earnings phase where investor focus is shifting away from headlines and into execution. For much of the past year, the AI narrative has carried technology valuations higher, with traders rewarding companies positioned as infrastructure winners. But as expectations rise, markets are becoming less interested in broad optimism and more focused on one key variable: hyperscaler capital spending guidance. The reason is simple. The largest technolog

Intel is back in focus for equity investors as the company attempts to prove that its turnaround is real and sustainable. After years of lost momentum in key growth segments, Intel is now benefiting from renewed demand in data center computing and a shift in sentiment driven by restructuring, strategic investment support, and a clearer roadmap for next generation chips. With earnings approaching, investors are watching one factor above all: guidance, and whether management ca

Healthcare stocks are gaining attention this week after AstraZeneca announced it will acquire Boston based Modella AI, a move that signals a new phase in how major drugmakers approach artificial intelligence. Instead of relying only on partnerships and limited collaborations, large pharmaceutical firms are increasingly choosing to buy AI capabilities outright and integrate them deep into their research process. Investors are reading this acquisition as a strategic statement:

Memory chip stocks are gaining attention this week after Micron announced it will acquire a fabrication plant from Taiwan’s Powerchip Semiconductor Manufacturing in a cash deal. The move is being interpreted as a strategic bet on long term memory demand, particularly as the AI boom reshapes the global semiconductor supply chain. Investors see this as more than a simple asset purchase. It is a signal that memory producers are positioning aggressively for the next phase of AI i